New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
09:15 EDTYHOO, JASO, ICPT, LO, BMY, FPRX, WPX, VRSN, GMCR, HTZ, SINA, HNROn The Fly: Pre-market Movers
UP AFTER EARNINGS: JA Solar (JASO), up 16%. ALSO HIGHER: Five Prime (FPRX), up 13% after signing collaborative agreement with Bristol-Myers (BMY)... SINA (SINA), up 9% after files preliminary prospectus to raise up to $500M in U.S. IPO of Weibo unit... Hertz (HTZ), up 7.7% after Financial Times says the company is nearing a spin-off of its construction equipment rental business... Lorillard (LO), up 2.5% following upgrade at Goldman... Keurig Green Mountain (GMCR), up 3.7% after being selected to replace WPX Energy (WPX) in S&P 500 as of March 21 close... Yahoo (YHOO), up 4.1% after Alibaba announces plan to begin U.S. IPO process... LOWER: Intercept (ICPT), down 0.6% after disclosing two serious adverse events in Phase 2 FLINT trial... Harvest Natural (HNR), down 10% after earnings report. VeriSign (VRSN), down 5% after the National Telecommunications and Information Administration said it intends to transition key Internet domain name functions.
News For YHOO;SINA;HTZ;GMCR;VRSN;WPX;FPRX;BMY;LO;ICPT;JASO;HNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 10, 2014
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
06:48 EDTLOSenators call on FDA to adopt strict e-cigarette warning
Subscribe for More Information
October 9, 2014
14:37 EDTYHOOYahoo looking to make Tumblr another YouTube, Business Insider says
Subscribe for More Information
10:21 EDTWPXWPX Energy says will explore opportunistic, bolt-on acquisitions
Subscribe for More Information
10:15 EDTWPXWPX Energy sees increasing market cap threefold by 2020
Says about 100 employees chose to accept early exit program. Sees year end employee headcount down about 15% from year end 2013. Says about 70%-80% of capital is oil focused. Says production guidance "in line" with previously provided view. Says expects to increase market capitalization threefold by 2020; says this belief is not reliant on M&A, bolt on acquisitions. Says targeting $12B market cap by 2020. Sees fivefold increase in oil production by 2020. Says bullish longer term for natural gas. Sees nat gas pricing $3.50-$4.50 over next three years, sees oil market at $80.00-$100.00 a barrel. Comments made on the company's strategy rollout conference call. WPX Energy shares are down 4.78% to $20.53 in morning trading.
09:59 EDTWPXWPX Energy sees Q3 adjusted production 1,060-1,073.3 MMcfe/d
Subscribe for More Information
09:56 EDTWPXWPX Energy reaffirms adjusted full-year production guidance
WPX Energy reaffirmed its full-year production guidance ranges, adjusted for its Powder River sale. In the Williston, WPX says its initial result of larger stimulations encouraging. In San Juan Gallup, WPX says it is completing first two 7,500ʹ laterals and that a 3rd rig has been added. Guidance and comments from slides for strategic update.
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
06:13 EDTGMCRKeurig Green Mountain implied volatility of 34 at lower end of index mean range
October 8, 2014
16:44 EDTWPXWPX Energy outlines multi-year strategy
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
11:38 EDTHTZStocks with call strike movement; GPRO HTZ
Subscribe for More Information
11:10 EDTHTZOptions with increasing implied volatility
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTBMYBristol-Myers resolves outstanding U.S. litigation on efavirenz
Bristol-Myers Squibb Company says it has "successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva -- efavirenz -- and Atripla products. Accordingly, we believe that loss of exclusivity in the U.S. for efavirenz should not occur until December 2017. Bristol-Myers Squibb remains committed to delivering our medicines and to developing new and innovative treatments to help patients prevail over serious disease. Atripla is currently the #1 prescribed U.S. regimen in its category, with over 8 million prescriptions written since its launch in 2006. Earlier this year the company submitted a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate and cobicistat, an investigational pharmacokinetic enhancer. In addition, studies are ongoing for new treatments including an HIV-1 attachment inhibitor, an HIV-1 maturation inhibitor and an anti-PD-L1. The establishment of intellectual property rights allows Bristol-Myers Squibb to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We will continue to defend our intellectual property rights against infringement as we remain focused on providing a deep and broad portfolio of innovative medicines to patients around the world."
07:18 EDTBMYInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
06:19 EDTYHOOYahoo lays off 400 employees in India, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use